CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD Insider Trading

CHECK POINT Director Jerry T Ungerman sold 25,000 shares ($3.1M) via 10b5-1 plan; retains 16,167 shares

Jerry T Ungerman, a director at CHECK POINT SOFTWARE TECHNOLOGIES LTD, sold 25,000 shares at $122.55 on 2026-06-11 for a total value of $3,063,632.50, reducing his non-derivative holdings from 41,167 shares to 16,167 shares. This transaction was executed under a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. The stock currently trades at $123.46, down 46.8% from its 52-week high of $232.07 and off 19.8% over the past 90 days. The sale represents a reduction of 60.7% of his pre-transaction holdings, though derivative holdings remain at zero.

Director Shenhav Tal Shavit sells 25,000 CHKP shares at $123.07 for $3.1M under pre-arranged 10b5-1 plan

Shenhav Tal Shavit (Director) sold 25,000 shares at $123.07 on 2026-06-11 under a pre-arranged 10b5-1 trading plan, reducing non-derivative holdings from 29,008 shares to 4,008 shares. The sale occurs as CHKP trades at $123.46, -46.8% from the 52-week high of $232.07 and -19.8% from the 90-day opening. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, it does not represent a timing decision by the insider and should be interpreted as an automatic portfolio execution. The insider retains 4,008 non-derivative shares post-transaction, and derivative holdings show 0 options remaining in direct holdings.

CHKP director Yoav Chelouche sold 25,000 shares ($3.5M) at $140.28 under 10b5-1 plan; holds 4,008 shares post-sale

Director Yoav Chelouche sold 25,000 shares (25.0K shares) of CHECK POINT SOFTWARE TECHNOLOGIES LTD (CHKP) at $140.28 on 2026-06-02 for a total value of $3,506,940.00 ($3.5M), reducing non-derivative holdings from 29,008 shares to 4,008 shares. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning the sale was scheduled in advance and not a discretionary decision made in response to current conditions. At the current price of $135.68, the stock is trading 42.0% below its 52-week high of $233.78 and has declined 17.5% over the past 90 days, though it gained 16.1% over the past 30 days. As a scheduled trade under a 10b5-1 plan, this sale reflects predetermined portfolio execution rather than a timing signal about the company's prospects.